Abstract: Provided is a T lymphocyte. The T lymphocyte expresses a chimeric antigen receptor, and includes an extracellular region. The extracellular region includes a first single-chain antibody, a second single-chain antibody, a first linker peptide, and a CD8 hinge region. The first linker peptide is arranged between the first single-chain antibody and the second single-chain antibody. The first single-chain antibody includes a first heavy chain variable region, a first light chain variable region, and a second linker peptide. The second linker peptide is arranged between the first heavy chain variable region and the first light chain variable region. The second single-chain antibody includes a second heavy chain variable region, a second light chain variable region, and a third linker peptide. The third linker peptide is arranged between the second heavy chain variable region and the second light chain variable region.

Abstract: Provided is an antibody or antigen-binding fragment thereof that can specifically recognize CD22. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence at least 95% identical thereto: a heavy-chain variable region CDR sequence: SEQ ID NOs: 1-15, and a light-chain variable region CDR sequence as shown in SEQ IN NOs: 16-30. The antibody can specifically recognize CD22 and has high affinity to CD22.

Abstract: The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

Abstract: The present invention provides a nucleotide sequence for encoding CAR, a ROBO1 CAR-NK cell of expressing the CAR, and preparation and application thereof. The ROBO1 CAR-NK cell provided by the present invention can specifically kill tumor cells by using ROBO1 antibody for the construction of CAR-NK cells and using ROBO1 molecules as target antigens. It can be used as a therapeutic agent for tumor diseases, for the treatment of tumor with highly expressing of ROBO1, without harmful phenomena such as cytokine release syndrome, thus providing new treatments for the tumors which are ineffective in traditional surgery, chemotherapy and radiotherapy. It has lower toxicity, higher safety and better specific lysis activity compared with ROBO1 CAR-T cell.

Abstract: Provided is a T lymphocyte. The T lymphocyte co-expresses a fusion protein and a chimeric antigen receptor, and the chimeric antigen receptor identifies a tumor antigen, herein the chimeric antigen receptor includes: an extracellular region; a transmembrane region, herein the transmembrane region is connected to the extracellular region, and embedded into a cell membrane of a transgenic lymphocyte; and an intracellular region, herein the intracellular region is connected to the transmembrane region, and the intracellular region includes an immune co-stimulatory molecule intracellular segment. The fusion protein includes: an immune checkpoint single-chain antibody and a T cell activation molecule.

Abstract: The present invention relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

Abstract: Provided is an antibody, which is capable of specifically binding to a B-cell maturation antigen (BCMA). The provided BCMA antibody is capable of specifically binding to an extracellular fragment of the BCMA and has excellent affinity and specificity; and the antibody is a functional antibody and has the activity blocking binding of the BCMA with its ligand APRIL. Immune cells constructed based on the antibody has an excellent specific killing function for a BCMA-positive tumor cell.

Abstract: Provided are a PD-1 CAR NK-92 cell and a preparation method and use thereof. The PD-1 CAR NK-92 cell expresses PD-1-CD8™-4-1BB-CD3? fusion protein in NK-92 cells. The PD-1 CAR NK-92 is obtained by infecting an NK92 cell line with a PD-1 CAR molecule and obtaining monoclonal cells by means of flow screening, and culturing and expanding CAR NK92 monoclonal cell strains with stable traits and a high killing activity. The cells can be produced on a large scale, can be used in different patients without GVHR rejection, and have a specific killing activity and significant therapeutic effect on tumors.

Abstract: A chimeric antigen receptor (CAR) and a gene encoding the CAR. The CAR comprises an extracellular domain capable of binding to an antigen, a transmembrane domain, and intracellular immune co-stimulatory molecule, wherein the extracellular domain comprises a D2 domain of a Slit2 protein. A chimeric antibody-expressing cell, which introduces a gene encoding the CAR into a cell so as to express the CAR on the surface of the cell. The CAR or CAR-expressing cell can be used as a cell drug for the treatment of tumor diseases. By using the CAR for engineering cells, especially T cells, the engineered T cells can specifically recognize and kill tumors, and have higher tumoricidal activity.

Abstract: A multimodal transportation interworking system at least comprises: a rail system; a cargo vehicle (31), which may be movably disposed on a rail beam of the rail system (30); a transfer apparatus (32), for transferring a goods loading device (33) from a transportation tool to the cargo vehicle (31) and loading onto the cargo vehicle, or unloading the goods loading device (33) from the cargo vehicle and conveying the same onto the transportation tool; a processor, which is connected to the cargo moving device (31) and the transfer apparatus (32) so as to control the transfer apparatus to transfer the goods loading device, and after the goods loading device is secured onto the cargo vehicle, to control the cargo vehicle to move on the rail beam.

Abstract: A movable side wall and opening/closing mechanism for railroad boxcars, comprising a side wall assembly (1), an end-portion opening/closing mechanism (2), a hinged rod assembly (3), a lateral door central clamping device (4), a upper transmission shaft assembly (5), a lower transmission shaft assembly (6), a upper track assembly (7) and a lower track assembly (8); upon loading/unloading cargo, the movable side wall can be opened further, so as to allow multiple forklifts of any tonnage on the ground to load/unload cargo to/from any positions of a carriage; the hinged rod assembly (3) and the central clamping device (4) are provided to keep the movable side wall reliably closed in order to ensure security and self-locking during transportation.

Abstract: The present invention provides a nucleotide sequence for encoding CAR, a ROBO1 CAR-NK cell of expressing the CAR, and preparation and application thereof. The ROBO1 CAR-NK cell provided by the present invention can specifically kill tumor cells by using ROBO1 antibody for the construction of CAR-NK cells and using ROBO1 molecules as target antigens. It can be used as a therapeutic agent for tumor diseases, for the treatment of tumor with highly expressing of ROBO1, without harmful phenomena such as cytokine release syndrome, thus providing new treatments for the tumors which are ineffective in traditional surgery, chemotherapy and radiotherapy. It has lower toxicity, higher safety and better specific lysis activity compared with ROBO1 CAR-T cell.

Abstract: The present invention discloses a connecting rod type two-level locking device, a hopper car bottom door and a hopper car, and belongs to the technical field of rail wagons. The connecting rod type two-level locking device includes a transmission shaft, a door opening arm, a first roller, a second roller, a first locating pin, a standstill locking disk and a linkage mechanism. The hopper car bottom door includes the connecting rod type two-level locking device. The hopper car includes the bottom door. Even if the connecting rod type two-level locking device is accidentally stressed, the linkage mechanism cannot rotate, and at this time, the slave arm cannot rotate neither. The accidental opening of the hopper car bottom door can be avoided. The hopper car is more reliable to use.

Abstract: The present invention relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD- 11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

Abstract: The invention provides an engineering vehicle having a ballast unloading device (100) and a ballast leveling device (200). The engineering vehicle includes a vehicle body (10), and the ballast unloading device (100) and the ballast leveling device (200) arranged on the vehicle body (10). The ballast unloading device (100) includes: a ballast carrying portion (20) provided with ballast unloading openings (21), and the ballast carrying portion (20) being arranged on the vehicle body (10); ballast unloading doors (30) capable of rotating relative to the ballast carrying portion (20), inner unloading passages (31) and outer unloading passages (32) being arranged on the ballast unloading doors (30), the ballast unloading doors (30) further including stop portions (33) located between the inner unloading passages (31) and the outer unloading passages (32).

Abstract: A dual-system electronic apparatus and a terminal include an open operating system and an encryption operating system, and further include: a first processor used for correspondingly processing data of the open operating system; a second processor used for correspondingly processing data of the encryption operating system; and a communication unit coupled to the first processor and the second processor, the communication unit being used for data interaction with the exterior. During running, the electronic apparatus can receive an instruction, the open operating system is set as a running system, and the encryption operating system runs in background; or the encryption operating system is set as the running system, and the open operating system runs in background.

Abstract: A multimodal transportation interworking system at least comprises: a rail system; a cargo vehicle (31), which may be movably disposed on a rail beam of the rail system (30); a transfer apparatus (32), for transferring a goods loading device (33) from a transportation tool to the cargo vehicle (31) and loading onto the cargo vehicle, or unloading the goods loading device (33) from the cargo vehicle and conveying the same onto the transportation tool; a processor, which is connected to the cargo moving device (31) and the transfer apparatus (32) so as to control the transfer apparatus to transfer the goods loading device, and after the goods loading device is secured onto the cargo vehicle, to control the cargo vehicle to move on the rail beam.

Abstract: Provided are a PD-1 CAR NK-92 cell and a preparation method and use thereof. The PD-1 CAR NK-92 cell expresses PD-1-CD8™-4-1BB-CD3? fusion protein in NK-92 cells. The PD-1 CAR NK-92 is obtained by infecting an NK92 cell line with a PD-1 CAR molecule and obtaining monoclonal cells by means of flow screening, and culturing and expanding CAR NK92 monoclonal cell strains with stable traits and a high killing activity. The cells can be produced on a large scale, can be used in different patients without GVHR rejection, and have a specific killing activity and significant therapeutic effect on tumors.

Abstract: A chimeric antigen receptor (CAR) and a gene encoding the CAR. The CAR comprises an extracellular domain capable of binding to an antigen, a transmembrane domain, and intracellular immune co-stimulatory molecule, wherein the extracellular domain comprises a D2 domain of a Slit2 protein. A chimeric antibody-expressing cell, which introduces a gene encoding the CAR into a cell so as to express the CAR on the surface of the cell. The CAR or CAR-expressing cell can be used as a cell drug for the treatment of tumor diseases. By using the CAR for engineering cells, especially T cells, the engineered T cells can specifically recognize and kill tumors, and have higher tumoricidal activity.

Abstract: A movable side wall and opening/closing mechanism for railroad boxcars, comprising a side wall assembly (1), an end-portion opening/closing mechanism (2), a hinged rod assembly (3), a lateral door central clamping device (4), a upper transmission shaft assembly (5), a lower transmission shaft assembly (6), a upper track assembly (7) and a lower track assembly (8); upon loading/unloading cargo, the movable side wall can be opened further, so as to allow multiple forklifts of any tonnage on the ground to load/unload cargo to/from any positions of a carriage; the hinged rod assembly (3) and the central clamping device (4) are provided to keep the movable side wall reliably closed in order to ensure security and self-locking during transportation.